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Diabetic heart disease is a distinct clinical entity that can progress to heart failure
and sudden death. However, the mechanisms responsible for the alterations in
excitation-contraction coupling leading to cardiac dysfunction during diabetes are not well
known. Hyperglycemia, the landmark of diabetes, leads to the formation of advanced
glycation end products (AGEs) on long-lived proteins, including sarcoplasmic reticulum
(SR) Ca2+ regulatory proteins. However, their pathogenic role on SR Ca2+ handling in
cardiac myocytes is unknown. Therefore, we investigated whether an AGE cross-link
breaker could prevent the alterations in SR Ca2+ cycling that lead to in vivo cardiac
dysfunction during diabetes. Streptozotocin-induced diabetic rats were treated with
alagebrium chloride (ALT-711) for 8 weeks and compared to age-matched placebo-treated
diabetic rats and healthy rats. Cardiac function was assessed by echocardiographic
examination. Ventricular myocytes were isolated to assess SR Ca2+ cycling by confocal
imaging and quantitative Western blots. Diabetes resulted in in vivo cardiac dysfunction
and ALT-711 therapy partially alleviated diastolic dysfunction by decreasing isovolumetric
relaxation time and myocardial performance index (MPI) (by 27 and 41% vs. untreated
diabetic rats, respectively, P < 0.05). In cardiac myocytes, diabetes-induced prolongation
of cytosolic Ca2+ transient clearance by 43% and decreased SR Ca2+ load by 25%
(P < 0.05); these parameters were partially improved after ALT-711 therapy. SERCA2a
and RyR2 protein expression was significantly decreased in the myocardium of untreated
diabetic rats (by 64 and 36% vs. controls, respectively, P < 0.05), but preserved in the
treated diabetic group compared to controls. Collectively, our results suggest that, in a
model of type 1 diabetes, AGE accumulation primarily impairs SR Ca2+ reuptake in cardiac
myocytes and that long-term treatment with an AGE cross-link breaker partially normalized
SR Ca2+ handling and improved diabetic cardiomyopathy.
Keywords: cardiomyopathy, sarcoplasmic reticulum Ca2+-ATPase pump, diastolic function, type 1 diabetes,
alagebrium chloride (ALT-711)
INTRODUCTION
Diabetes has become an epidemic disease and it is estimated that
by the year 2025, it will affect over 300 million people worldwide
(Amos et al., 1997; Boudina and Abel, 2007). In the United States
alone, about 8% of the population is affected by diabetes and
approximately one million of those people suffer from insulin-
dependent (type 1) diabetes. Type 1 diabetes is characterized
by sustained hyperglycemia resulting from the loss of insulin-
producing pancreatic beta cells. This loss in insulin production
results in dysfunctional glucose uptake in insulin-sensitive tissues
(e.g., striated muscle) and causes multiple-organ complications.
Of importance, diabetes is also a common cause of cardiovascular
diseases. Within the past 30 years, diabetic cardiomyopathy has
been identified as its own clinical unit, independent of coronary
artery disease and atherosclerosis (Fang et al., 2004; Poornima
et al., 2006). Ventricular diastolic dysfunction is the first stage of
diabetic cardiomyopathy and has been reported in about 50% of
asymptomatic patients (Fang et al., 2004; Lacombe et al., 2007).
Because intracellular calcium (Ca2+) homeostasis is crucial for
excitation-contraction coupling, chronic diabetes mellitus has
been associated with impaired cardiac contractility and relaxation
of the myocardium due to altered Ca2+ homeostasis (Lagadic-
Gossmann et al., 1996; Pierce and Russell, 1997; Netticadan et al.,
2001; Zhong et al., 2001; Choi et al., 2002; Fang et al., 2004;
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Lacombe et al., 2007). However, the exact mechanisms for this
impaired Ca2+ homeostasis and the specific therapeutic strategies
for this patient population remain elusive.
The sarcoplasmic reticulum (SR) functions as the main regu-
lator of intracellular Ca2+ and is a major determinant of cardiac
contraction and relaxation (Bers, 2002). Ca2+ entry through the
L-type Ca2+ channel activates Ca2+ release from the SR. The SR
Ca2+ release channels, the ryanodine receptors (RyRs), release the
majority of free Ca2+ necessary for contraction, and SR Ca2+
ATPase (SERCA2a) pumps sequester the majority of Ca2+ dur-
ing relaxation of cardiac myocytes. Several groups (including
ours) have reported decreased expression of these SR Ca2+ reg-
ulatory proteins in type 1 diabetic rats with cardiac dysfunction
(Poornima et al., 2006; Lacombe et al., 2007; Ratnadeep et al.,
2009). Furthermore, impaired excitation-contraction coupling in
diabetic myocytes has been characterized by slower Ca2+ tran-
sient decays and cytosolic Ca2+ overload during the diastolic
phase (Pierce and Russell, 1997; Choi et al., 2002; Lacombe et al.,
2007). However, the mechanisms by which SR Ca2+ cycling is
impaired during diabetic cardiomyopathy have not been fully
elucidated.
Chronic hyperglycemia, the hallmark of diabetes, accelerates
the reaction between glucose and proteins and leads to the
formation of advanced glycation end products (AGEs). These
AGEs form irreversible cross-links throughout the lifetime of
many large proteins (such as collagen and hemoglobin), cova-
lently modifying their structure and function (Cooper, 2004).
Therefore, AGEs induce myocardial fibrosis and stiffness leading
to severe cardiac dysfunction (Norton et al., 1996; Asif et al., 2000;
Vaitkevicius et al., 2001; Aronson, 2003; Candido et al., 2003;
Bakris et al., 2004; Cooper, 2004; Hartog et al., 2007; Ma et al.,
2009). In addition, Bidasee et al. (2003, 2004) have demonstrated
the presence of cross-linked AGEs on long-lived intracellular car-
diac SR proteins such as the SERCA2a pump and RyR2 after a
few weeks of diabetes. Therefore, one could hypothesize that the
post-translational modifications of the SR proteins by AGEs could
lead to an alteration in Ca2+ homeostasis. However, the func-
tional significance of AGEs on SR Ca2+ regulatory proteins in
cardiac myocytes and thus on excitation-contraction coupling has
not been determined. Our hypothesis was that treatment with an
antiglycation therapeutic agent, dimethyl-3-phenacylthiazolium
chloride (alagebrium chloride or ALT-711), which chemically
breaks AGE cross-links, will normalize SR Ca2+ reuptake in car-




Eight-week-old male Wistar rats were randomly divided into 3
groups (n = 11/group): untreated age-matched control group
(CON); untreated diabetic group (DX); and ALT-711 (Shanghai
Inc., China) treated diabetic group (DX-ALT). Diabetes was
induced at 10 weeks of age in DX and DX-ALT groups by
a single injection of streptozotocin (STZ, 50 mg/kg IP diluted
in 1 mL citrate buffer). The control group received similar
volume of vehicle. One diabetic group received dimethyl-3-
phenacylthiazolium chloride (ALT-711, 10 mg/kg per day in the
drinking water) for 8 weeks. This therapeutic dose has been
previously shown to significantly reduce cardiac AGE level in
STZ-induced diabetes (Candido et al., 2003). The volume of
ALT-711 delivered in the drinking water was calculated based on
the individual water consumption, which was measured every
other day. To confirm the status of diabetes, venous blood
samples were drawn from the tail vein for measurement of
blood glucose concentration using a glucometer (BD Logic)
at baseline and then weekly after STZ injection for 8 weeks.
Animals were weighed once a week, as a means to monitor
their clinical condition. This animal protocol was approved by
the Ohio State University Institutional Animal Care and Use
Committee.
ECHOCARDIOGRAPHY
Transthoracic echocardiographic examination was performed to
assess systolic and diastolic function at baseline and 8 weeks
after the induction of diabetes. Two-dimensional, M-mode, and
pulsed-wave Doppler imaging were obtained in rats lightly
anesthetized with isoflurane (minimal effective concentration),
and placed on a heating table to maintain normothermia.
Examinations were done using a high-resolution high-frequency
digital imaging system with a 21 MHz linear-array transducer
and simultaneous ECG recording (Vevo 2100, VisualSonics,
Toronto, Canada), following standard techniques as previously
described (Dirksen et al., 2007; Lacombe et al., 2007, 2010; Ware
et al., 2011). Standard parasternal long- and short-axis views
(6–8/rat) were obtained during each echocardiographic exami-
nation. Ventricular structure and function were assessed by two-
dimensional cine loops of a long-axis view (with frame rates of
at least 200 frames/s) and of a short-axis view at mid-level of the
papillary muscles, as well as M-mode loops of the short-axis view.
Thicknesses of the interventricular septum and of the left ventric-
ular posterior wall, and left ventricular internal diameter (LVID)
were measured in systole and diastole from the short-axis view
according to standard procedures. Left ventricular (LV) ejection
fraction (EF), a surrogate of systolic function, was calculated, as
follows: EF = (LVID end-diastolic – LVID end-systolic/LVID end-
diastolic) × 100%. The apical four-chamber view was used for
color flow guided, pulsed-wave Doppler imaging of transmitral
flow and LV outflow. The myocardial performance index (MPI
or TEI index) was obtained from the sum of the LV isovolumic
relaxation time and isovolumic contraction time divided by the
aortic ejection time, parameters which were measured from the
pulsed-wave Doppler imaging of transmitral flow and LV out-
flow. Echocardiographic image measurements were performed
offline. All image acquisitions and offline measurements were
conducted by the same investigator (AK). Average values were
obtained from the measurement of three cardiac cycles from one
cine loop.
MASSON TRICHROME STAINING
LV fibrosis was measured at 8 weeks after the induction of diabetes
by the Ohio State University’s Core Pathology laboratory. LV cross
sections were washed with PBS, fixed using OCT (optimal cut-
ting temperature) compound, frozen in dry ice and stained with
Masson Trichrome staining.
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VENTRICULAR MYOCYTE ISOLATION
Following echocardiographic measurements, animals were euth-
anized by pentobarbital sodium. The heart was removed and
perfused in a retrograded manner, using a Langendorff apparatus
with tyrode buffer (37◦C, pH = 7.35 and oxygenated with 95%
O2 and 5% CO2), which contained (in mM): NaCl (135), KCl
(5.4), MgCl 2 (1), NaH2PO4 (0.33), Hepes (10), glucose (10), and
CaCl2 (1). This initial perfusion was followed by a perfusion with
tyrode buffer without any CaCl2. Subsequently, collagenase (type
II, Worthington Biochemical, 1 mg/ml) was added to the calcium
free tyrode buffer and recirculated for the rest of the perfusion
period. When the heart was soft, the ventricles were minced and
the cells were subsequently washed in tyrode solution containing
CaCl2 (1). Only rod-shaped cells with sharp margins and clear
striations were included in the study. All recordings were made
within 5 h of isolation (Dirksen et al., 2007; Lacombe et al., 2007,
2010).
MEASUREMENT OF Ca2+ TRANSIENT AND SR Ca2+ LOAD
Ca2+ transient was measured in fluo-3-loaded cardiac myocytes
with confocal Ca2+ imaging as previously described; for measure-
ments of Ca2+ transients and transient decay, mean area under
the curve was calculated (Kubalova et al., 2005; Dirksen et al.,
2007; Lacombe et al., 2007, 2010). Rapid applications of caffeine
(10 mM) were used to measure SR Ca2+ content by measur-
ing the peak amplitude of the caffeine-induced Ca2+ transients.
Intracellular Ca2+ imaging was performed using a Laser Scanning
Confocal System (Olympus Fluoview 1000 confocal microscope
interfaced to an IX-70 inverted microscope and equipped with
an 60 × 1.4 NA oil objective). Fluo-3 was excited by the 488- nm
beam of an argon-ion laser, and the fluorescence was acquired
at wavelengths > 515 nm in the line scan mode, at a rate of
2 or 6 ms per scan. The magnitude of fluorescent signals was
quantified in terms of F/F0, where F0 is baseline fluorescence
(Kubalova et al., 2005; Dirksen et al., 2007; Lacombe et al., 2007,
2010).
MEASUREMENTS OF SR Ca2+ REGULATORY PROTEINS
LV myocardium was collected 8 weeks after the induction
of diabetes. Crude membrane homogenates were prepared for
Western blot analysis, as previously described (Meurs et al.,
2006; Lacombe et al., 2007; Ware et al., 2011). Proteins
were subjected to sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) electrophoresis, electrophoretically
transferred to PVDF membranes using a trans-blot cell (Bio-
Rad Laboratories, Hercules, CA, USA; Meurs et al., 2006;
Lacombe et al., 2007; Ware et al., 2011). Samples from the
3 groups were loaded on the same gel to ensure equal blot-
ting conditions for each group. Membrane proteins were incu-
bated with mouse RyR2 or SERCA2a antibodies (1:3000 and
1:1000 dilution, respectively, Affinity Bioreagents), and sub-
sequently with the appropriate secondary antibodies conju-
gated to horseradish peroxidase (1:50,000 dilution, Jackson
ImmunoResearch Laboratories; 1:5000 dilution, Sigma Aldrich,
respectively). Quantitative determination of protein was per-
formed by autoradiography after revealing the antibody-bound
protein by enhanced chemiluminescence reaction. The data were
normalized to actin or calsequestrin, previously quantified by
reprobing each membrane with calsequestrin polyclonal IgG
(Calbiochem) or Actin monoclonal IgG (Sigma Aldrich), respec-
tively.
STATISTICAL ANALYSIS
A Two-Way ANOVA (treatment and time factors) for the in vivo
measurements, and a one-way analysis of variance (treatment
factor) for the in vitro measurements were performed, as appro-
priate. Data were reported as means ± SE. Statistical significance
was defined as P < 0.05.
RESULTS
As expected, the STZ-treated rats exhibited hyperglycemia within
72 h post injection, which persisted during the 8-week exper-
imental period (P < 0.05, Figure 1). Treatment with an AGE
cross-link breaker, ALT-711, for 8 weeks did not significantly alter
blood glucose concentration compared with untreated diabetic
rats. In addition, the diabetic rats had a significantly lower body
weight when compared to the control group and there was a ten-
dency (P < 0.1) for the treated diabetic rats to have a higher body
weight than the untreated diabetic rats at 4 and 8 weeks after the
induction of diabetes (Figure 2).
In vivo VENTRICULAR FUNCTION
We then evaluated the effect of diabetes and ALT-711 therapy on
systolic and diastolic function by echocardiographic examination
in (treated and untreated) diabetic and control groups. EF, a sur-
rogate of systolic function, was mildly decreased at 8 weeks after
the induction of diabetes compared to baseline values (Table 1).
In addition, the isovolumic relaxation time and the MPI, two
parameters of LV relaxation, were significantly increased in
untreated diabetic rats compared to the age-matched control
groups (Table 2). ALT-711 therapy did not significantly alter EF
of the diabetic myocardium but blunted the increase in isovolu-
mic relaxation time and the MPI in diabetic animals, suggesting
FIGURE 1 | Blood glucose was significantly increased in DX and
DX-ALT groups compared to age-matched control group. Mean ± SE of
blood glucose concentration in control (CON), untreated diabetic (DX),
treated diabetic (DX-ALT) rats at baseline (time 0) and up to 8 weeks after
the induction of diabetes. n = 10 − 11/group. ∗P < 0.05 when comparing
values from age-matched controls.
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FIGURE 2 | Body weight was significantly decreased in DX and DX-ALT
groups compared to age-matched control group. Mean ± SE of body
weight in control (CON), untreated diabetic (DX), treated diabetic (DX-ALT)
rats at baseline (time 0) and 8 weeks after the induction of diabetes.
n = 10 − 11/group. ∗P < 0.05 when comparing values from age-matched
controls. †P < 0.1 when comparing values from DX group.
that ALT-711 therapy partially prevented cardiac dysfunction by
primarily improving diastolic dysfunction (Figure 3 and Table 2).
Because diastolic dysfunction may be due to reduced rate of
sequestration of Ca2+ into the SR or to histological changes
in myocardium rendering it less compliant, hearts were stained
with Masson’s trichrome to quantify fibrosis. Masson trichrome
staining did not reveal significant fibrosis of the left ventricle in
(treated and untreated) diabetic rats compared with the control
group, suggesting primarily an impaired ventricular relaxation
rather than increased myocardial stiffness in our diabetic model
(Figure 4).
MEASUREMENT OF Ca2+ TRANSIENT AND SR Ca2+ LOAD
Because AGEs accumulate on SR Ca2+ regulatory proteins and
could alter their function leading to diabetic cardiomyopathy, we
further determined if treatment with an AGE cross-link breaker
would improve SR Ca2+ handling during diabetic cardiomy-
opathy by measuring Ca2+ transient in fluo-3-loaded cardiac
myocytes with confocal Ca2+ imaging. There was a significant
Table 1 | Parameters derived from M-mode echocardiography of LV for age-matched control (CON), untreated diabetic (DX), treated diabetic
(DX-ALT) groups at baseline and at 8 weeks after the induction of diabetes.
CON DX DX-ALT
Baseline 8 weeks Baseline 8 weeks Baseline 8 weeks
EF (%) 85.7 ± 2.6 84.4 ± 1.8 86.11 ± 2.02 67.8 ± 2.54∗# 83.7 ± 2.08 73.8 ± 0.14∗#
FS (%) 57.7 ± 3.11 55.7 ± 2.22 57.7 ± 2.50 39.6 ± 2.07∗# 54.4 ± 2.42 44.5 ± 1.71∗#
IVS;d (cm) 1.85 ± 0.07 2.11 ± 0.07 2.05 ± 0.07 1.85 ± 0.10 2.02 ± 0.10 1.84 ± 0.09
IVS;s (cm) 3.42 ± 0.07 3.76 ± 0.14# 3.64 ± 0.11 2.94 ± 0.09∗# 3.54 ± 0.10 3.15 ± 0.09∗#
LVID;d (cm) 6.46 ± 0.22 7.39 ± 0.13# 6.47 ± 0.16 7.74 ± 0.17# 6.59 ± 0.26 7.75 ± 0.2#
LVID;s (cm) 2.79 ± 0.29 3.29 ± 0.21# 2.74 ± 0.19 4.69 ± 0.22∗# 3.00 ± 0.19 4.32 ± 0.20∗#
LVPW;d (cm) 1.64 ± 0.07 1.84 ± 0.09 1.70 ± 0.08 1.63 ± 0.10 1.63 ± 0.08 1.60 ± 0.08
LVPW;s (cm) 3.17 ± 0.12 3.43 ± 0.1# 3.11 ± 0.12 2.57 ± 0.08∗# 2.95 ± 0.12 2.67 ± 0.14∗
LV Mass;c (mg) 610.1 ± 42.5 891.3 ± 36.2# 676.8 ± 35.8 812.9 ± 70.4# 663.2 ± 35.3 792.6 ± 41.2
LV Vol;d (ul) 216.5 ± 16.5 289.6 ± 11.3# 215.9 ± 11.45 322.1 ± 15.9# 226.6 ± 19.6 323.2 ± 18.4#
HR (b/min) 329.6 ± 9.21 318.24 ± 8.64 344.7 ± 2.00 243.8 ± 7.95∗# 335.4 ± 10.5 268.3 ± 6.02∗#
Data are mean ± SE for n = 9 – 11/group. IVS;s: interventricular septal dimension-systole, IVS;d: interventricular septal dimension-diastole, LVPW;s: left ventricular
posterior wall dimension-systole, LVPW;d: left ventricular posterior wall dimension-diastole, LVID;s: left ventricular internal diameter-systole, LVID;d: left ventricular
internal diameter-diastole; LV Mass;c: left ventricular mass corrected, EF: ejection fraction, FS: fractional shortening, HR: heart rate. ∗P < 0.05 when comparing
values from age-matched controls for same time point. #P < 0.05 when comparing values from baseline.
Table 2 | Doppler-derived parameters of diastolic function for age-matched control (CON), untreated diabetic (DX), treated diabetic (DX-ALT)
groups at baseline and at 8 weeks after the induction of diabetes.
CON DX DX-ALT
Baseline 8 weeks Baseline 8 weeks Baseline 8 weeks
MV E/A 1.52 ± 0.06 1.52 ± 0.06 1.62 ± 0.092 1.64 ± 0.080 1.59 ± 0.11 1.82 ± 0.15
IVRT 22.4 ± 0.83 25.4 ± 1.07 23.0 ± 0.95 44.98 ± 1.88∗# 24.8 ± 1.14 37.3 ± 2.07∗†
MV Dec Acc (mm/s2) 38647.0 ± 4166.0 34047.0 ± 4493.3 39465.7 ± 3418.6 39593.8 ± 8829.9 40454.0 ± 4650.1 26790.0 ± 2305.4
LV MPI 0.54 ± 0.04 0.57 ± 0.05 0.46 ± 0.03 0.76 ± 0.08∗# 0.61 ± 0.04 0.56 ± 0.08†
Data are mean ± SE for n = 9 – 11/group. MV E, maximum velocity of the E wave; MV A, maximum velocity of the A wave; MV E/A, ratio of E and A wave;
IVRT, isovolumic relaxation time; MV Dec Acc, maximum velocity deceleration acceleration; LV MPI, left ventricle myocardial performance index. ∗P < 0.05 when
comparing values from age-matched controls for same time point. #P < 0.05 when comparing values from baseline. † P < 0.05 when comparing DX values vs.
DX-ALT.
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FIGURE 3 | ALT-711 therapy partially alleviated diabetic cardiomyopathy
by primarily improving Doppler-derived parameters of diastolic function.
(A) A representative paired M-mode echocardiograms (top panel) and
transmitral Doppler flow (bottom panel) at 8 weeks of treatment in control
(Con), untreated diabetic (DX), and treated diabetic (DX-ALT) groups. IVS,
interventricular septum; LVPW, left ventricular posterior wall; RV, right
ventricle; IVRT: isovolumic relaxation time. (B) Mean ± SE of percentage
change after 8 weeks of treatment compared to baseline value for ejection
fraction (EF) of the left ventricle (LV) in control (Con), untreated diabetic (DX),
and treated diabetic (DX-ALT) groups. (C) Mean ± SE of percentage change
at 8 weeks compared to baseline value for isovolumic relaxation time (IVRT)
of the left ventricle in control (Con), untreated diabetic (DX), and treated
diabetic (DX-ALT) groups. (D) Mean ± SE of percentage change at 8 weeks
compared to baseline value for myocardial performance index (MPI) in
control (Con), untreated diabetic (DX), and treated diabetic (DX-ALT)
groups. n = 9 − 11/group,∗P < 0.05 when comparing values from
age-matched controls. †P < 0.05 when comparing values from
DX group.
(P < 0.001) decrease in Ca2+ transient amplitude in isolated
cardiac myocytes of (untreated and treated) diabetic rats when
compared with controls (Figure 5). In addition, the Ca2+ tran-
sient decay during the diastolic phase was significantly prolonged
in diabetic compared with control myocytes (Figure 5). ALT-711
therapy resulted in shortening of the Ca2+ transient decay, sug-
gesting an improvement in SR Ca2+ reuptake in treated diabetic
myocytes. In addition, SR Ca2+ load, measured by caffeine-
evoked Ca2+ transient amplitudes, was significantly decreased in
myocytes from untreated diabetic, but not from treated diabetic
rats, compared with control groups (Figure 5), suggesting that
ALT-711 therapy partially attenuated SR Ca2+ content depletion
in diabetic myocytes.
MEASUREMENT OF SR Ca2+ REGULATORY PROTEINS
To determine if AGE accumulation could alter the expres-
sion of SR Ca2+ regulatory protein, we performed quantita-
tive immunoblot analysis of SERCA2a and RyR2. SERCA2a
pump expression was significantly decreased in the myocardium
of untreated diabetic, but not from treated diabetic rats,
compared with control groups. We also observed a decrease in
RyR2 protein expression in the myocardium of diabetic rats
when compared to controls, while the diabetic treated group
exhibited similar RyR2 protein levels compared with controls
(Figure 6).
DISCUSSION
The major finding of this study was that long-term treatment with
ALT-711, an AGE cross-link breaker, partially restored SR Ca2+
handling in cardiac myocytes, by primarily improving Ca2+ tran-
sient decay compared to the untreated diabetic rats. As a result,
ALT-711 therapy partially prevented in vivo diastolic dysfunction
in the diabetic myocardium of a rodent model of type 1 diabetes.
The STZ diabetic rat model is a well-established model to
study insulin-dependent (type 1) diabetes. STZ contains a glu-
cose molecule with a highly reactive nitrosourea side chain,
which initiates a specific cytotoxic action on the pancreatic β-cell.
A few weeks after STZ injection, rodents develop biochemical
and functional myocardial abnormalities, which are the result
of chronic hyperglycemia rather than a direct effect of the drug
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FIGURE 4 | Lack of fibrosis in ventricle of (untreated and treated)
diabetic rats. (A) Masson Trichrome staining showing fibrosis (Fibrosis
Control experiment). (B–D) Representative Trichrome staining (×20 objective)
demonstrating the lack of ventricle fibrosis in age-matched
control (Con), untreated diabetic (DX), and treated diabetic (DX-ALT)
groups.
itself. Therefore, diabetic rodents display clinical signs (hyper-
glycemia, polydipsia, glycosuria, and polyuria) and cardiovascular
complications similar to those in human diabetic patients. Since
a close relationship between the STZ dose and the severity of dia-
betes has been demonstrated and since other parameters (such
as animal strain, frequency or route of injection, or prepara-
tion of STZ, and duration of diabetes) all significantly influence
the severity of the model, we previously established in our lab-
oratory a protocol (using a low dose of STZ) to induce a mild
form of diabetes and to mimic the early metabolic and cardiac
events that occur in diabetic subjects (Lacombe et al., 2007). As a
result, the mortality rate was less than 5% and all the rats became
diabetic. Importantly, these diabetic rats develop primarily mild
diastolic dysfunction followed by mild systolic dysfunction, have
prolonged QTs and action potential durations and are prone to
arrhythmias (Lacombe et al., 2007, 2010). In addition, this animal
model is somewhat relevant to non-insulin-dependent diabetic
(or type 2) subjects, who also develop diabetic cardiomyopathy
(Boudina and Abel, 2007). Indeed, while initially there is insulin
resistance in type 2 diabetes, as the disease progresses there is
also insulin deficiency secondary to the exhaustion of pancre-
atic beta cells (which have produced large amounts of insulin to
compensate for the insulin resistance).
Diabetic heart disease, also referred to as diabetic cardiomy-
opathy, is a major cause of cardiovascular diseases in the United
States today. It can lead to heart failure and sudden death, killing
∼65% of the patient population (Choi et al., 2002). The presence
of LV diastolic dysfunction is an early complication of diabetes
and is the first stage in the development of diabetic cardiomyopa-
thy (Fang et al., 2004; Lacombe et al., 2007). Diastolic dysfunction
refers to mechanical and functional abnormalities such as impair-
ment of diastolic distensibility, filling, or relaxation of the left
ventricle (Aurigemma et al., 2006). The incidence of diastolic
dysfunction has been underestimated until the recent advance-
ment of non-invasive imaging tools of cardiac relaxation, such as
Doppler flow and tissue Doppler imaging. In particular, the MPI
is a Doppler-derived parameter independent of blood pressure
and load. MPI increases with worsening of LV diastolic dysfunc-
tion, even during the early stages of subclinical diastolic dys-
function (Su et al., 2006). Early determination of this myocardial
manifestation of diabetes is of major importance, since subclini-
cal diastolic dysfunction contributes to a four to eightfold increase
in risk for congestive heart failure in diabetic patients (Piccini
et al., 2004). As previously reported by our group (Lacombe
et al., 2007, 2010), this animal model displayed mild diastolic dys-
function, as evident by the alterations of Doppler flow-derived
parameters (i.e., increased isovolumic relaxation time and MPI).
Since early relaxation is an active process regulated by SR Ca2+
handling, impaired myocardial relaxation is characterized by dis-
turbances in calcium homeostasis rather than by fibrosis (Fang
et al., 2004; Lacombe et al., 2007). Similarly, we did not detect
significant amount of fibrosis in (untreated and treated) diabetic
rats, suggesting that the impaired ventricular relaxation rather
than increased myocardial stiffness primarily accounts for the
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FIGURE 5 | ALT-711 therapy ablated the prolongation of Ca2+ transient
decay in diabetic cardiac myocytes. (A) Representative confocal line
scan images of Ca2+ transient along with their spatial averages in
myocytes from age-matched control (CON, left), untreated diabetic
(DX, middle), and treated diabetic (DX-ALT, right) rats. F0, diastolic
fluorescence. (B) Mean ± SE of Ca2+ transient amplitude (F/F0) for CON,
DX, and DX-ALT rats, n = 43 − 44/group. (C) Mean ± SE of the time constant
(τ) of Ca2+ transient decay in CON, DX, and DX-ALT rats. n = 40 ± 4/group.
τ decay is significantly increased in DX compared to CON (P < 0.05). Please
note a significant decrease in DX-ALT compared to DX, showing an
improvement in calcium reuptake time after 8 weeks of ALT-711 treatment.
(D) Caffeine-induced Ca2+ transient amplitudes (mean ± SE) were
reduced in myocytes from diabetic compared with control and treated
diabetic rats. n = 4 − 5/group, ∗P < 0.05 when comparing values from
age-matched control myocytes. †P < 0.05 when comparing values from DX
group.
negative lusitrope manifested during ventricular filling in our
type 1 diabetic model. This is in agreement with previous stud-
ies that reported no difference in myocardial collagen (vs. control
group) in a similar type 1 diabetic model exhibiting mild diastolic
dysfunction (Dent et al., 2001). In addition, it has been suggested
that diabetes mellitus can produce diastolic dysfunction before
the development of myocardial fibrosis due to formation of AGEs,
although the mechanisms were not investigated (Norton et al.,
1996; Fang et al., 2004). Therefore, this model of mild diastolic
dysfunction allows us to evaluate the effect of AGEs on ventricular
relaxation and its underlying alterations in SR Ca2+ homeostasis
before the development of marked fibrosis.
AGEs are proteins that accumulate in the plasma of diabetic
patients as a result of the persistent hyperglycemia and are closely
linked with cardiovascular diseases. During diabetes, and to a
lesser extent during aging, AGEs also accumulate at an accelerated
rate in various cell types (in days to weeks) and produce multiple-
organ dysfunction (Cooper, 2004; Hartog et al., 2007). In the
heart, AGE accumulation contributes to diastolic dysfunction, by
inducing myocardial fibrosis and stiffness (Norton et al., 1996;
Asif et al., 2000; Vaitkevicius et al., 2001; Aronson, 2003; Candido
et al., 2003; Liu et al., 2003; Bakris et al., 2004; van Heerebeek
et al., 2008). However, its role in the development of diastolic
dysfunction secondary to impaired ventricular relaxation, deter-
mined principally by the rate of resequestration of Ca2+ into
the SR rather than by an increased myocardial fibrosis, is not
known. In the present study, we investigated a novel mechanism
by which AGE accumulation functionally impairs SR Ca2+ regu-
latory proteins (especially SERCA pump), by use of an antiglyca-
tion therapeutic agent: dimethyl-3-phenacylthiazolium chloride
(alagebrium chloride or ALT-711), which chemically breaks AGE
cross-links. This compound has been tested in several pre-clinical
animal studies, and has been shown to significantly reduce cardiac
AGE level in STZ-induced diabetic rats and prevent diabetes-
induced structural changes in the myocardium (Asif et al., 2000;
Vaitkevicius et al., 2001; Candido et al., 2003; Liu et al., 2003;
Vasan et al., 2003; Bakris et al., 2004; Cooper, 2004). In con-
trast with inhibitors of AGE cross-link (e.g., aminoguanidine),
AGE cross linkage breakers prevent but also reverse the cross-
link process once it has already been established (Norton et al.,
1996). Therefore, one could argue that similar beneficial ther-
apeutic effects of ALT-711, as the ones observed in this study,
could be obtained once diabetic cardiomyopathy has been estab-
lished. Since ALT-711 therapy was administered at the onset of
diabetes in our study, further studies will be required to con-
firm its therapeutic effect in subjects with established diabetes.
Overall, our in vivo data suggested that long-term treatment with
ALT-711 improved the clinical condition of treated diabetic rats,
as evident by the increase (although not statistically significant)
in body weight. Importantly, ALT-711 therapy partially improved
diastolic function, as evident by the attenuation of the prolon-
gation in isovolumic relaxation time and MPI observed in treated
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FIGURE 6 | ALT-711 therapy partially attenuated the decreased
expression of SR Ca2+ regulatory proteins in the diabetic myocardium.
(A) Top panel: representative immunoblot of sarco(endo)plasmic reticulum
Ca2+ -ATPase (SERCA2a) and calsequestrin (loading control) expression in
the myocardium of control (CON), untreated diabetic (DX), treated diabetic
(DX-ALT) groups; samples were from the same membrane, which was
reprobed for calsequestrin (the loading control). Within the same gel, the
reassembly of noncontiguous lanes has been demarcated by white spaces.
Bottom panel: normalized optical density (OD; relative to calsequestrin) of
SERCA2a protein content was significantly decreased in DX, but not in
DX-ALT, hearts compared to control group. Data are mean ± SE for
n = 4 − 5/group. (B) Top panel: representative immunoblot of Ryanodine
Receptor (RyR2) protein expression in the myocardium of control (CON),
untreated diabetic (DX), treated diabetic (DX-ALT) hearts (samples were
from the same membrane, which was reprobed for actin, the loading
control. Within the same gel, the reassembly of noncontiguous lanes has
been demarcated by white spaces). Bottom panel: normalized optical
density (relative to actin, loading control) of RyR2 protein was significantly
decreased in DX, but unchanged in DX-ALT, hearts compared to control
group. Data are mean ± SE for n = 5/group. ∗P < 0.05 when comparing
values from age-matched control heart.
diabetic rats. In addition, because of the lack of significant fibrosis
in the diabetic myocardium, our data suggested that the beneficial
therapeutic effects of ALT-711 were primarily due to improved
ventricular relaxation.
In isolated cardiac myocytes of diabetic animals, we observed
prolonged Ca2+ transient decay, reduced intra-SR Ca2+ stores
and Ca2+ transient amplitude and decreased SERCA2a protein
content, which are all consistent with decreased SR Ca2+ reuptake
during the relaxation phase, as previously reported by our group
(Lacombe et al., 2007). Extensive studies have tried to unravel
metabolic disturbances and intracellular targets that lead to
impaired Ca2+ homeostasis and to the diabetic cardiomyopathic
phenotype, a complex multifactorial disorder (Poornima et al.,
2006). AGE accumulation during diabetes, and to a less extent
during aging, could contribute to the observed cardiomyopa-
thy, since AGEs form irreversible cross-links with many proteins
with low turnover rates, such as collagen but also intracellular
cardiac SR proteins (i.e., SERCA2a pump and RyR2); however,
their pathogenic role on excitation-contraction coupling has not
been investigated. Since treatment with AGE crosslink breakers
has been shown to completely prevent or reduce the forma-
tion of AGEs (Wolffenbuttel et al., 1998; Cooper et al., 2000;
Vaitkevicius et al., 2001; Candido et al., 2003; Vasan et al., 2003;
Forbes et al., 2004), ALT-711 treatment could have a poten-
tial beneficial effect on the function of SR Ca2+ regulatory
proteins. Following ALT-711 therapy, we observed a normal-
ization of the Ca2+ transient decay, and a partial restoration
of intra-SR Ca2+ stores and SERCA2a protein expression in
diabetic cardiac myocytes. These data suggested that ALT-711
treatment decreased excess accumulation of AGEs on the SERCA
pump by breaking the cross-links that form during diabetic car-
diomyopathy, resulting in partial improvement of SERCA activity
and SR Ca2+ reuptake. The enhanced SR Ca2+ reuptake dur-
ing the relaxation phase of cardiac myocytes resulted in partial
improvement of in vivo diastolic function in treated diabetic
subjects.
In contrast, treatment with the AGE cross-link breaker for
8 weeks did not normalize Ca2+ transient amplitude in isolated
diabetic myocytes. In correlation with these in vitro findings, we
observed a moderate, but persistent, reduction of cardiac con-
tractility in diabetic animals treated with ALT-711, as evident
by the mild decrease in EF in both untreated and treated dia-
betic animals. One surprising finding was the persistent decrease
in Ca2+ transient amplitude in the face of partially restored
SR Ca2+ load and RyR2 protein expression in the diabetic
myocardium after ALT-711 treatment. Since abnormal SR Ca2+
release during diastole has been reported in diabetic myocytes
(Shao et al., 2007), one could hypothesize that ALT-711 therapy
may also improve Ca2+ homeostasis by stabilizing RyR medi-
ated SR Ca2+ release during the relaxation phase of diabetic
cardiac myocytes and that AGE accumulation may also impair
RyR function leading to diastolic SR Ca2+ leak. Therefore, these
data further support the concept that AGE accumulation may play
a larger pathogenic role during diastolic dysfunction and dias-
tolic heart failure than during systolic dysfunction (Hartog et al.,
2007).
CONCLUSIONS AND CLINICAL SIGNIFICANCE
Treatment with an AGE cross-link breaker partially attenu-
ated the alterations associated with cardiac function and SR
Ca2+ handling during diabetic cardiomyopathy. Since diabetic
cardiomyopathy is a multifactorial disorder, these data sug-
gest that AGE accumulation contributes to the impairment in
excitation-contraction coupling by altering the function of SR
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Ca2+ regulatory proteins, leading to a decreased ability for the
diabetic myocardium to relax. Therefore, findings from this study
provide novel mechanistic insights related to the pathogenic role
of AGE accumulation on SR Ca2+ handling in cardiac myocytes.
Finally, since there is currently a lack of specific therapy to
improve LV relaxation, findings from this study could have direct
practical implications for the development of therapeutic strate-
gies for patients with diabetic cardiomyopathy.
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